As BFW pointed out earlier, the entire difference in MACE can be attributed almost entirely to the eGFR<60 patients.
Since the action seems to be concentrated in those kidney disease patients that were given Apabetalone, I suspect Don McCaffrey's real fire works come from, Monday morning...in his slides.